iotalamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 1469 2276-90-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iothalamic acid
  • iotalamic acid
  • methalamic acid
  • iothalamate meglumine
  • meglumine iotalamate
  • iothalamate sodium
A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
  • Molecular weight: 613.92
  • Formula: C11H9I3N2O4
  • CLOGP: 0.55
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 3
  • TPSA: 95.50
  • ALOGS: -3.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.98 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 30, 1963 FDA MALLINCKRODT

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AA04 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, high osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:37338 contrast media
CHEBI has role CHEBI:78298 environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.1 acidic
pKa2 13.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
N0000166657 NUI
D01258 KEGG_DRUG
4018169 VANDF
4018170 VANDF
CHEBI:31713 CHEBI
CHEMBL1201300 ChEMBL_ID
13087-53-1 SECONDARY_CAS_RN
1225-20-3 SECONDARY_CAS_RN
DB09133 DRUGBANK_ID
DB00271 DRUGBANK_ID
1546451 RXNORM
4908 MMSL
000669 NDDF
002344 NDDF
004528 NDDF
004956 NDDF
395982009 SNOMEDCT_US
783807009 SNOMEDCT_US
C0022034 UMLSCUI
D007483 MESH_DESCRIPTOR_UI
D007482 MESH_DESCRIPTOR_UI
CHEMBL1201125 ChEMBL_ID
CHEMBL1097620 ChEMBL_ID
1371 INN_ID
3737 PUBCHEM_CID
16CHD79MIX UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cysto-Conray II HUMAN PRESCRIPTION DRUG LABEL 1 0019-0862 INJECTION 172 mg URETERAL NDA 19 sections
Conray HUMAN PRESCRIPTION DRUG LABEL 1 0019-0953 INJECTION 600 mg INTRAVASCULAR NDA 20 sections
Conray HUMAN PRESCRIPTION DRUG LABEL 1 0019-0953 INJECTION 600 mg INTRAVASCULAR NDA 20 sections
Conray HUMAN PRESCRIPTION DRUG LABEL 1 0019-0953 INJECTION 600 mg INTRAVASCULAR NDA 20 sections